Our mission:

NeuroScios was initially founded as a company specialized in consulting for drug development in the field of neurodegenerative disorders with a specific focus on Alzheimer’s Disease. Manfred Windisch PhD, the founder of the company has about 35 years of experience in that particular field in his history in academia, the pharmaceutical industry and including 17 years of running a specialized pre-clinical and clinical CRO for neurodegenerative disorders. All of the co-workers have a similar experience in academic as well as industrial research and drug development programs.

NeuroScios is able to help to accelerate drug development programs based on the profound knowledge in all steps from early discovery to clinical trials. We are also linked with extremely experienced service providers in the field. One of the examples is the company PsychoGenics Inc., which is one of the world leading experts in in-vivo pharmacology of CNS disorders, offering full service from behavior, via electrophysiology to brain biochemistry and histology. We have a wide spectrum of collaboration partners and can also help to find the most appropriate vendors to perform specific tasks and we can provide help in writing protocols, quality control and surveillance of such studies, assessment and interpretation of data and report writing. Similar experience and partnerships are established in the field of pharmacokinetics, safety pharmacology and toxicology. Our expert team in regulatory affairs can provide consultation for interaction with regulatory agencies like EMA or FDA (FDA via established partnerships).

NeuroScios has also a small group that helps to design, organize and supervise clinical trials in that field from Phase 1 to Phase 2B. Here the expertise comprises challenging studies including CSF sampling, PET imaging, structural MRI and complex neuropsychological testing. The company has outstanding experience in quantitative pharmaco-EEG, management of multi-site MRI and PET studies including all needed standardization procedures, finally quantitative assessment and statistics of such studies. NeuroScios provides also a proprietary unique spatial navigation task (AMUNET) which is an interesting experimental cognitive task with extreme sensitivity in the early stage of dementia (early MCI), progression and treatment.

In summary our mission is to provide optimized services to allow a straight forward approach to clinical trials for new compounds or treatment procedures, or an early failure. Our team can support this services on an international level, our clinical programs are mainly run in Europe, but together with an American partner company also in North America.
Our internal drug development:

NeuroScios is also working in the development of new compounds to treat Alzheimer’s Disease and related protein misfolding disorders. Our approach is addressing the self-supporting aggregation (prionoid) of disease relevant proteins and addresses aggregate propagation, neurodegeneration and deposition of such toxic protein species. Out of a chemical space of several hundred molecules we have already identified a few lead candidates and characterized them in-vitro and in-vivo models of Alzheimer’s Disease. These compounds are penetrating blood brain barrier and are highly tolerable without any signs of toxicity in the performed studies. In these investigations they show a dose-dependent decrease of soluble and insoluble brain Abeta, but also a reduction of paired helical filament-TAU load, which results in an increase of synaptic density and finally improved learning and memory capabilities. Another advantage of the compounds is that they are intrinsically fluorescent and so they can also be used to label such protein aggregates and a development into theranostics would be feasible.

At the moment NeuroScios is in the stage of fundraising to move the program from the preclinical stage into regulatory toxicology/safety pharmacology and aims towards Phase I clinical trials in Q3/Q4 2016.

For any further information please contact Manfred Windisch, PhD (please find the contact details above mentioned).